TrialHuman vaccines & immunotherapeutics2015

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.

Ting Fan Leung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.